Cancer Drug Pipeline Tracking Update

As of March 31, 2017
Objectives of Update

- Review oncology drugs in the pipeline being tracked ending March 31, 2017
- Allocation of 2017 Manufacturers’ Survey Results
- Identify key trends

Purpose of Tracking

The pCODR Pipeline Tracker systematically identifies and monitors novel oncology drugs and new indications for pre-existing oncology drugs for the purposes of:

- Gaining awareness of emerging trends in oncology treatment
- Assisting provincial drug programs, cancer agencies and pCODR with proactive health system planning, resource allocation, and possibly prioritization for implementation.
## Manufacturers’ Survey Results

<table>
<thead>
<tr>
<th>Year</th>
<th>Manufacturers</th>
<th>Distinct Drugs</th>
<th>New Drugs</th>
<th>New Indications</th>
<th>Drug-Indication Pairs</th>
<th>New Drugs</th>
<th>New Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013-2014</td>
<td>18</td>
<td>71</td>
<td>62</td>
<td>29</td>
<td>197</td>
<td>119</td>
<td>27</td>
</tr>
<tr>
<td>2015</td>
<td>14</td>
<td>94</td>
<td>67</td>
<td>27</td>
<td>235</td>
<td>176</td>
<td>59</td>
</tr>
<tr>
<td>2016</td>
<td>18</td>
<td>108</td>
<td>70</td>
<td>38</td>
<td>313</td>
<td>198</td>
<td>115</td>
</tr>
<tr>
<td>2017</td>
<td>16</td>
<td>93</td>
<td>62</td>
<td>31</td>
<td>277</td>
<td>148</td>
<td>122</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4 radio-pharmaceutical</td>
<td></td>
<td>3 biosimilar products</td>
<td></td>
</tr>
</tbody>
</table>
Distribution by Route of Administration

- Oral: 54%
- Intravenous: 44%
- Intradermal: 1%
- Subcutaneous: 1%
Distribution by Trial Status

- Phase 3: 56%
- Phase 2: 44%
Distribution by Tumour Site
Distribution by Companion Diagnostic Tests

Companion test 27%
none 73%

- ALK: 3
- BCR-ABL: 1
- BRAF: 3
- BRCA: 11
- CMET: 4
- EGFR T790: 3
- FGFR2: 1
- FLT3: 3
- GCC: 8
- HER2 BREAST: 12
- HER2 GI: 1
- PD-L1: 2
- PIK3CA: 1
- TP53: 20
- UNDER DEVELOPMENT: 20
Some Factors Influencing Submissions to pCODR

Not all drugs and indications undergoing trials will result in a submission to pCODR

- Manufacturer decides not to seek regulatory approval in Canada. Health Canada does not issue NOC
- Manufacturer decides not to submit for national funding review
- Manufacturer decides to submit on interim results of phase 3 trial
- Manufacturer decides to submit with phase 2 data
- Trial fails to meet primary endpoints or halted due to serious adverse events